Gilead in its press release further stated that purchasers of its shares between January 7 and January 28, 2013 will get a due-bill. The due bill will make the buyer eligible for an additional share for each share bought. We note that shares of Gilead Sciences have been on an uptrend since the beginning of the year driven by multiple positive catalysts, including the purchase of Pharmasset, targeting the lucrative hepatitis C virus (:HCV) market and the approval of the high potential HIV therapy, Stribild. The stock is currently hovering around its 52-week high of $76.28, reached on November 23, 2012. We believe that the soaring stock price necessitated the 2-for-1 stock split. Apart from the positive developments noted above, Gilead received further good news last month when it presented encouraging top-line data on its HCV candidate sofosbuvir from a phase III study.